Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.46 |
| ▸ | RARB | P10826 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.43 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5315791 | 0.83 | APEX1 (0.61) | APEX1HSD17B10CYP1A2CYP2C9HPGD | |
| SCHEMBL6477127 | 0.81 | RARB (0.54) | HPGDNPC1RAB9ASMN1; SMN2GRIN2D | |
| SCHEMBL5315809 | 0.81 | APEX1 (0.63) | APEX1HSD17B10CYP1A2CYP2C9HPGD | |
| SCHEMBL6489146 | 0.81 | APEX1 (0.58) | APEX1HSD17B10CYP1A2CYP2C9HPGD | |
| SCHEMBL15199295 | 0.81 | APEX1 (0.58) | APEX1HSD17B10CYP1A2CYP2C9HPGD | |
| SCHEMBL7814196 | 0.81 | APEX1 (0.58) | APEX1HSD17B10CYP1A2CYP2C9HPGD | |
| SCHEMBL6489046 | 0.80 | APEX1 (0.65) | APEX1HSD17B10CYP1A2CYP2C9HPGD | |
| SCHEMBL1448835 | 0.79 | APEX1 (0.56) | APEX1HSD17B10CYP1A2CYP2C9HPGD | |
| SCHEMBL16344775 | 0.78 | APEX1 (0.67) | APEX1HSD17B10CYP1A2CYP2C9HPGD | |
| SCHEMBL6477384 | 0.78 | APEX1 (0.58) | APEX1HSD17B10CYP1A2CYP2C9HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887863-B2 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES (US) | 2005-05-03 | — | — | US | disclosed |
| EP-1272456-B1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LAB (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| EP-1272456-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | Abbott Laboratories (US) | 2003-01-08 | — | — | EP | disclosed |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES | 2002-01-03 | — | — | US | disclosed |
| WO-2001079157-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | APEX1 1768/4885HSD17B10 1675/4885CYP1A2 1673/4885 |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | APEX1 1768/4885HSD17B10 1675/4885CYP1A2 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.